Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021779

Enrollment

Unknown

Registered

2019-03-09

Start date

2019-03-15

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

Case series:NO

Eligibility

Sex/Gender

All

Age

29 Years to 74 Years

Inclusion criteria

Inclusion criteria: Patients with histologically and laboratory proven MM between April 2015 and January 2019 were included in this analysis.

Exclusion criteria

Exclusion criteria: The following patients were excluded: 1) MM patients who had additional malignancies; 2) Time interval between baseline and post-treatment scans 25 weeks; 3) Patients who received radiation therapy.

Design outcomes

Primary

Measure	Time frame
ADC;	—

Countries

China

Contacts

Public ContactChunhong Hu

the First Affiliated Hospital of Soochow University

hch5305@163.com+86 13506219750

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026